Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 2686  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (637 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 » Introduction
 »  Materials and Me...
 » Results
 » Discussion
 » Conclusion
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    Viewed1884    
    Printed37    
    Emailed1    
    PDF Downloaded100    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
ORIGINAL ARTICLE
Year : 2015  |  Volume : 63  |  Issue : 4  |  Page : 537-541

A study on cognitive decline with respect to metabolic syndrome and inflammation in elderly Indians


1 Department of Medicine, ESI-PGIMSR and ESIC Medical College, Joka, Kolkata, India
2 Department of Medicine, Medical College and Hospital, Kolkata, India
3 Department of Nephrology, IPGME and R, Kolkata, West Bengal, India

Date of Web Publication4-Aug-2015

Correspondence Address:
Anirban Ghosh
Flat No D2/4, Debjan Apartment, 334 NSC Bose Road, Kolkata - 700 047, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.162037

Rights and Permissions

 » Abstract 

Background: This study was undertaken to find out if metabolic syndrome (MetS) in the elderly was associated with cognitive decline and also if this association was modified by the presence of inflammation.
Materials and Methods: 100 patients more than 60 years of age were divided into 2 groups of 50 each and were age and sex matched. Group 1 and 2 had patients with and without MetS, respectively. The individual components of MetS were measured in each patient. Cognitive decline was measured by Modified Mini-Mental Score (3MS) of Teng. Inflammation was measured by high-sensitivity C-reactive protein (hs-CRP).
Results: Fasting hyperglycemia was the most common component of MetS (60% of group 1). The mean serum hs-CRP in patients of group 1 was 6.56 ± 9.72 while that in the patients of group 2 was 1.95 ± 1.93. In the group-1, 36% (n = 18) patients were having a decreased 3MS, whereas in group-2, 22% (n = 11) were having a decreased 3MS. MetS was associated with an odd's ratio of 1.99 for developing cognitive decline. 3MS had a negative correlation with hs-CRP values. Regression analysis showed a significant association of hs-CRP and MetS with cognitive decline in the elderly population.
Conclusion: Cognitive decline in the elderly is associated with the presence of inflammation and MetS. Hence, early identification of the high-risk groups may offer benefit by disease course modification and better caregiving.


Keywords: Cognitive decline; elderly; high sensitivity C-reactive protein; metabolic syndrome


How to cite this article:
Ghosh A, Biswas AK, Banerjee A. A study on cognitive decline with respect to metabolic syndrome and inflammation in elderly Indians. Neurol India 2015;63:537-41

How to cite this URL:
Ghosh A, Biswas AK, Banerjee A. A study on cognitive decline with respect to metabolic syndrome and inflammation in elderly Indians. Neurol India [serial online] 2015 [cited 2019 Oct 17];63:537-41. Available from: http://www.neurologyindia.com/text.asp?2015/63/4/537/162037



 » Introduction Top


As modern management of diseases has improved with a greater understanding of the disease processes, the number of people living beyond the age of 60 years has also increased rapidly. Besides ageing, the high prevalence of obesity and the related co-morbidities, particularly affecting the elderly population, are considered as major health care problems. [1] Insulin resistance, as the main underlying disorder of obesity-related diseases, is more pronounced in overweight and obese individuals. The degree of insulin resistance increases with increasing age, and the elderly are, therefore, at a higher risk of developing the cardiometabolic risk factors summarized as metabolic syndrome (MetS). [2],[3] It is widely accepted that cardiovascular risk factors play a role in the development of Alzheimer's diseases and vascular dementia. [4] In elderly patients, the diagnosis of MetS may be further related to a more pronounced cognitive decline and disability. [5] The identification and treatment of patients with MetS would, therefore, be an important approach to reduce morbidity and impairment in the elderly population.

Ageing is associated with increased inflammatory activity. [6] Serum C-reactive protein (CRP) is a sensitive marker for systemic low-grade inflammation and is an important predictor of the underlying presence of type 2 diabetes mellitus and of cardiovascular diseases. [7] Indeed, the level of inflammation in the setting of MetS may help to identify those at high risk of developing an adverse outcome.

This study was undertaken to investigate if MetS was associated with cognitive decline and also if the outcome was further modified by the level of inflammation.


 » Materials and Methods Top


This was an observational, prospective cross-sectional study conducted over a period of 18 months at a tertiary care hospital in eastern India. Fifty consecutive patients of age more than 60 years having MetS were selected in one group (group 1); and, another 50 consecutive patients of age more than 60 years without MetS were selected in another group (group 2), both after ensuring that the exclusion criteria had been compiled with. A total of 109 subjects were finally evaluated as 6 patients from group 1 and 3 patients from group 2 had to be excluded for failing to meet the inclusion criteria.

Metabolic syndrome was diagnosed in these patients according to the International Diabetes Federation (IDF) criteria [8] that is,

1. Waist circumference ≥90 cm for men and ≥80 cm for women

With two or more of the following:

2. Fasting triglycerides >150 mg/dl or on specific medication

3. High-density lipoprotein (HDL) cholesterol <40 mg/dl for men or <50 mg/dl for women

4. Blood pressure >130 mm of Hg systolic and >85 mm of Hg diastolic or previously diagnosed hypertension or on specific medication for hypertension

5. Fasting plasma glucose >100 mg/dl or previously diagnosed type-2 diabetes mellitus

Patients with known preexisting neurological or psychological diseases were excluded from the study. Those with conditions which can alter the cognitive functions or lipid profile like sepsis, chronic liver/kidney disease, malignancy, dyselectrolytemia, hypothyroidism, collagen vascular disease, congestive cardiac failure; and, seriously ill patients were also excluded from study.

A detailed clinical history and examination were undertaken that included examination of the blood pressure and height and weight measurement. The body mass index (BMI) was calculated by the standard equation: BMI = weight (in kg)/height (in m 2 ). Waist circumference was measured by a nonstretchable measuring tape snugly fitting at the midpoint between the lowest rib and the iliac crest in fasting state at the end of expiration. Modified Mini-Mental Score (3MS) Examination of Teng was used for assessment of cognitive impairment. [9] It is a brief general cognitive battery with components of orientation, concentration, language, praxis, immediate and delayed memory with a maximum (best) score of 100. Cognitive impairment was defined as a decline of 5 or more on 3MS. Among the laboratory investigations, complete hemogram, fasting and postprandial blood sugar, glycosylated hemoglobin, liver function test, thyroid stimulating hormone, serum sodium and potassium, urea and creatinine and fasting lipid profile values were recorded. Routine urine examination, chest X-ray and electrocardiogram were also done to evaluate the conditions of the exclusion criteria. Serum high sensitivity CRP (hs-CRP) was measured by a highly sensitive nephelometric assay. A level of >3 mg/dl was considered as 'high inflammation,' whereas a level <3 mg/dl was considered as 'low inflammation.'

Statistical analysis

Pearson's correlation, odd's ratio (OR), Chi-square test and linear and logistic regression were used to assess the associations of the variables at appropriate points. Descriptive statistics have been presented with mean, range, and standard deviation of the variables. All the data were analyzed using SPSS statistical software version 17.0 (published by SPSS Inc., IBM, Chicago).


 » Results Top


The patients were divided into 2 groups: Group 1 (cases) and group 2 (controls). The descriptive statistics of group 1 and 2 are shown in [Table 1] and [Table 2], respectively. The mean age in the group 1 was 69.52 ± 6.69 years (maximum = 86 years, minimum = 61 years). The mean age in the group 2 was 69.04 ± 6.76 years (maximum = 82 years, minimum = 60 years). Thus, both the groups had a similar age profile, and they were age matched. In the group 1, 40% (n = 20) were female and 60% (n = 30) were male subjects. In the group 2, 48% (n = 24) were female and 52% (n = 26) were male subjects. Thus, the two groups were sex-matched. The mean BMI of the patients in group 1 was 27.66 ± 2.28 kg/m 2 , while that in the patients in group 2 was 23.91 ± 1.27 kg/m 2 . Thus, most of the diabetic patients were overweight. The mean waist circumference of the patients with MetS was 97.46 ± 7.21 cm, while that in the patients without MetS was 80.44 ± 4.02 cm.
Table 1: Descriptive profile of group 1 (n=50)

Click here to view
Table 2: Descriptive profile of group 2 (n=50)

Click here to view


In group 1, it was found that among the components of MetS, increased fasting glucose was the most common component. It was present in 60% (n = 30) patients of MetS. Hypertension was present in 56% (n = 28) patients. Hypertriglyceridemia was present in 54% (n = 27) patients. Low HDL cholesterol was present in 52% (n = 26) patients; whereas in group 2, increased fasting glucose was present in 28% (n = 14) patients. Hypertension was present in 32% (n = 16) patients. Hypertriglyceridemia was present in 20% (n = 10) and low HDL cholesterol was present in 24% (n = 12) patients.

The mean serum hs-CRP in patients with MetS was 6.56 ± 9.72 mg/dl while that in patients without MetS was 1.95 ± 1.93 mg/dl. In group-1, 40% (n = 20) were having high inflammation, while in group-2, 24% (n = 12) were having high inflammation. In the former group, 16% (n = 8) patients were male and 24% (n = 12) were female. In the latter group, male and female subjects were 12% (n = 6) and 12% (n = 6), respectively.

The mean 3MS in the patients with MetS was 92.30 ± 6.97 while that in the patients without MetS was 94.66 ± 5.08. In group-1, 36% (n = 18) patients were having a decreased 3MS, while in group 2, 22% (n = 11) were having a decreased 3MS. In the former group, 18% (n = 9) were males and 18% (n = 9) were females. In the latter group, the male and female patients were 12% (n = 6) and 10% (n = 5), respectively.

The OR was calculated for the risk of development of dementia in MetS. An increased risk of dementia was found in patients of MetS with an OR of 1.994 with 95% confidence interval of 0.824-4.827. The hs-CRP values correlated strongly with reduction in 3MS both in patients with MetS (Pearson's correlation: −0.782, P < 0.001) and without MetS (Pearson's correlation: −0.548, P < 0.001). The Chi-square test was performed to assess for an association between raised hs-CRP values and the presence of dementia in patients with and without MetS. It revealed an association between elevated hs-CRP and dementia in patients with MetS (Pearson's Chi-square: 5.22, P < 0.05, phi coefficient: 0.323, P < 0.05). However, no significant association was seen in patients without MetS (P value: 0.774).

[Figure 1] and [Figure 2] show the regression pattern (linear and logistic) of hs-CRP and 3MS in patients belonging to group 1 and group 2, respectively. Adjusted R 2 values for group 1 patients are 62.7% as compared to 28.6% for group 2, thus emphasizing that more than 60% variance in the 3MS score can be accounted for by the raised hs-CRP in MetS as compared to <30% in the non-MetS group. The ANOVA showed statistical significance of the regression model in both the groups (P < 0.05). The standardized β for logistic regression was 2.219 for group 1 and 1.741 for group 2 P < 0.001 on both the occasions.
Figure 1: Regression between high sensitivity C - reactive protein and Modified Mini Mental Score in group 1

Click here to view
Figure 2: Regression between high sensitivity C - reactive protein and Modified Mini Mental Score in group 2

Click here to view



 » Discussion Top


In our cross-sectional comparative study, we found that the prevalence of cognitive decline was more in patients with MetS. Among the patients having MetS, those having high hs-CRP values were found to have developed greater cognitive decline than the ones having low hs-CRP values. Similar studies from the western countries by Yaffe et al. and Dik et al. had also shown similar results. [10],[11],[12] On the other hand, when we compared cognitive impairment in the elderly patients with MetS and having high inflammation, with elderly patients without MetS, it was found that cognitive impairment was significantly more in the former group. MetS was found to increase the risk of cognitive decline. Regression analysis also suggested that the presence of a high hs-CRP especially in the MetS group can influence the development of cognitive decline. From these results, it can be concluded that cognitive impairment is significantly modifiable by the presence of high inflammation. In addition to this, it was found that increased fasting glucose was the most common component of MetS, followed by hypertension, increased triglyceride and decreased high density lipoproteins. Some other studies, however, had hypertension as the most common component. [10],[11],[12],[13],[14] Our study revealed poorer glycemic control in Indian patients. Hs-CRP level was significantly more in elderly patients with MetS and its prevalence was also more in the elderly patients with MetS than in those without MetS. This finding was similar to other studies reported in the medical literature.

The mechanism of cognitive decline in patients with MetS is not very clear. However, there are few plausible explanations. There is a possibility of increased cerebrovascular disease involving both micro and macrocirculation in these patients. [15] There is evidence of increased amount of brain atrophy in patients with obesity. [16] Aggregations of β amyloid in the brain and increased neurofibrillary tangles have been found in patients having insulin resistance and hypertension, respectively, even in the absence of cognitive decline. [17]

The presence of inflammation in MetS is well-described in medical literature. [18],[19],[2]0[,21] The link between MetS and inflammation might be an underlying atherosclerosis, and it might be this atherosclerosis or the combined effect of atherosclerosis and inflammation, which is giving rise to the cognitive decline. [18],[20] Our study has shown that patients having both MetS and inflammation are doing worse than the ones not having MetS or inflammation, as far as the cognitive decline is concerned. Our study has also shown that both inflammation and MetS are accountable for by a significant variation in the cognitive scores. However, the cause-effect relationship between inflammation, MetS and cognitive decline is yet to be established and is controversial. Alternate theories indicating a genetic predisposition resulting in an increased inflammatory response and subsequent adverse outcomes including a cognitive decline have been proposed. [10]

To the best of our knowledge, our study is the first in the Indian population, which deals with cognitive decline, inflammation and MetS in the elderly. Our study will probably help in better understanding of MetS, especially in the geriatric population in India. As we have compared age and sex matched groups, the results obtained are less likely to be confounded. We have included hs-CRP as an indicator for inflammation, which is a very sensitive tool. CRP values measured by the highly sensitive methods have been found to be independent predictors of future cardiovascular morbidity and hence its measurement is recommended for cardiovascular risk assessment and management in apparently healthy individuals, as opposed to the standard CRP assays that are used for monitoring infections and other inflammatory conditions. [22],[23] Furthermore, the 3MS is internationally accepted as a standard measure of global cognitive function. It includes 4 more items with a more graded scoring than the Mini Mental Score examination (MMSE). The 3MS has been demonstrated to have a greater sensitivity with enhanced validity and reliability to a broader variety of cognitive functions than the MMSE. [9]

Our study has some limitations. It was a cross-sectional study. A longitudinal study, which would record the cognitive and inflammatory changes over a period of time, would have been more suitable. A small sample size, measurement of a single inflammatory marker, the inclusion of only hospital-based population, and the insensitivity of 3MS to detect cognitive changes were some of the other limitations of our study. Furthermore, the effect of therapeutic agents used for dyslipidemia and diabetes were not taken into account, which could have modified the result.


 » Conclusion Top


This study shows that cognitive decline in elderly is associated with the presence of inflammation and MetS. An early identification of the high-risk groups may offer benefit by disease course modification and better caregiving.

 
 » References Top

1.
Rössner S. Obesity in the elderly - A future matter of concern? Obes Rev 2001;2:183-8.  Back to cited text no. 1
    
2.
Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001;86:3574-8.  Back to cited text no. 2
    
3.
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.  Back to cited text no. 3
    
4.
Hayden KM, Zandi PP, Lyketsos CG, Khachaturian AS, Bastian LA, Charoonruk G, et al. Vascular risk factors for incident Alzheimer disease and vascular dementia: The Cache County study. Alzheimer Dis Assoc Disord 2006;20:93-100.  Back to cited text no. 4
    
5.
Yaffe K. Metabolic syndrome and cognitive disorders: Is the sum greater than its parts? Alzheimer Dis Assoc Disord 2007;21:167-71.  Back to cited text no. 5
    
6.
Straub RH, Cutolo M, Zietz B, Schölmerich J. The process of ageing changes the interplay of the immune, endocrine and nervous systems. Mech Ageing Dev 2001;122:1591-611.  Back to cited text no. 6
    
7.
Laaksonen DE, Niskanen L, Nyyssönen K, Punnonen K, Tuomainen TP, Valkonen VP, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004;47:1403-10.  Back to cited text no. 7
    
8.
Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - A new worldwide definition. Lancet 2005;366:1059-62.  Back to cited text no. 8
    
9.
Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987;48:314-8.  Back to cited text no. 9
    
10.
Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004;292:2237-42.  Back to cited text no. 10
    
11.
Yaffe K, Haan M, Blackwell T, Cherkasova E, Whitmer RA, West N. Metabolic syndrome and cognitive decline in elderly Latinos: Findings from the Sacramento Area Latino Study of Aging study. J Am Geriatr Soc 2007;55:758-62.  Back to cited text no. 11
    
12.
Dik MG, Jonker C, Comijs HC, Deeg DJ, Kok A, Yaffe K, et al. Contribution of metabolic syndrome components to cognition in older individuals. Diabetes Care 2007;30:2655-60.  Back to cited text no. 12
    
13.
Zuliani G, Volpato S, Galvani M, Blè A, Bandinelli S, Corsi AM, et al. Elevated C-reactive protein levels and metabolic syndrome in the elderly: The role of central obesity data from the InChianti study. Atherosclerosis 2009;203:626-32.  Back to cited text no. 13
    
14.
Yaffe K, Weston AL, Blackwell T, Krueger KA. The metabolic syndrome and development of cognitive impairment among older women. Arch Neurol 2009;66:324-8.  Back to cited text no. 14
    
15.
Launer LJ. Demonstrating the case that AD is a vascular disease: Epidemiologic evidence. Ageing Res Rev 2002;1:61-77.  Back to cited text no. 15
    
16.
Jagust W, Harvey D, Mungas D, Haan M. Central obesity and the aging brain. Arch Neurol 2005;62:1545-8.  Back to cited text no. 16
    
17.
Razay G, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol 2007;64:93-6.  Back to cited text no. 17
    
18.
Grundy SM. Inflammation, hypertension, and the metabolic syndrome. JAMA 2003;290:3000-2.  Back to cited text no. 18
    
19.
Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005;111:1448-54.  Back to cited text no. 19
    
20.
Haffner SM. The metabolic syndrome: Inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006;97:3A-11.  Back to cited text no. 20
    
21.
Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391-7.  Back to cited text no. 21
    
22.
Windgassen EB, Funtowicz L, Lunsford TN, Harris LA, Mulvagh SL. C-reactive protein and high-sensitivity C-reactive protein: An update for clinicians. Postgrad Med 2011;123:114-9.  Back to cited text no. 22
    
23.
Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D′Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S49-73.  Back to cited text no. 23
    


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow